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ABSTRACT
Objectives: To assess the feasibility of improving
identification of familial hypercholesterolaemia (FH) in
primary care, and of collecting outcome measures to
inform a future trial.
Design: Feasibility intervention study.
Setting: 6 general practices (GPs) in central England.
Participants: 831 eligible patients with elevated
cholesterol >7.5 mmol/L were identified, by search of
electronic health records, for recruitment to the
intervention.
Intervention: Educational session in practice; use of
opportunistic computer reminders in consultations or
universal postal invitation over 6 months to eligible
patients invited to complete a family history
questionnaire. Those fulfilling the Simon-Broome
criteria for possible FH were invited for GP
assessment and referred for specialist definitive
diagnosis.
Outcome measures: Rates of recruitment of eligible
patients, identification of patients with possible FH,
referral to specialist care, diagnosis of confirmed FH in
specialist care; and feasibility of collecting relevant
outcome measures for a future trial.
Results: Of 173 general practices, 18 were interested
in participating and 6 were recruited. From 831 eligible
patients, 127 (15.3%) were recruited and completed
family history questionnaires: 86 (10.7%) through
postal invitation and 41 (4.9%) opportunistically.
Among the 127 patients, 32 (25.6%) had a possible
diagnosis of FH in primary care. Within 6 months of
completing recruitment, 7 patients had had specialist
assessment confirming 2 patients with definite FH
(28.6%), and 5 patients with possible FH (71.4%).
Potential trial outcome measures for lipid tests, statin
prescribing and secondary causes of
hypercholesterolaemia were extracted using automated
data extraction from electronic records alone without
recourse to other methods.
Conclusions: The intervention is feasible to
implement in GP, and facilitates recruitment of patients
with raised cholesterol for targeted assessment and
identification of FH. Extracting data directly from
electronic records could be used to evaluate relevant
outcome measures in a future trial.
INTRODUCTION
Familial hypercholesterolaemia (FH) is one
of the most common inherited autosomal
dominant disorders and is associated with
elevated low-density lipoprotein cholesterol
levels. In the UK, around 1 in 500 to 1 in
200 people are affected by the heterozygote
form of this condition.1 Left untreated this
can lead to premature coronary heart
disease in those individuals affected.2 3
However, with appropriate lipid-lowering
treatment, intervention is highly effective
and life expectancy can return to normal.4
Despite the overwhelming case for treat-
ment and national guidelines recommending
early identiﬁcation, it is estimated that up to
80% of heterozygote FH still remain unrecog-
nised.5 6 Of most concern, individuals with
raised cholesterol levels documented in
general practice (GP) medical records may
not be recognised to have possible FH.
However, primary care is an ideal setting to
identify possible FH cases through identiﬁca-
tion of those with raised cholesterol and rele-
vant family histories. Current UK National
Institute for Health and Care Excellence
Strengths and limitations of this study
▪ This feasibility study was able to engage general
practices (GPs) and patients from underserved
populations in an intervention to identify familial
hypercholesterolaemia (FH) more systematically.
▪ Extraction of data using automated GP computer
searches can capture important outcome mea-
sures for a future trial of FH identification.
▪ Further strategies are needed if engaging eligible
patients is to be improved on opportunistic
contact during GP consultations.
▪ The 6-month patient follow-up period used was
too short to elicit complete data on all relevant
outcome measures, such as eventual specialist
assessment.
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(NICE) guidelines recommend that these patients are
identiﬁed using Simon-Broome criteria (box 1).6 7
Using these criteria, a positive family history is based
on patients recalling premature coronary heart disease
or raised cholesterol levels in their ﬁrst-degree and/or
second-degree relatives. This level of detail is absent or
poorly recorded in GP electronic health records
(EHRs),8 so further work to collate the family history is
required, such as using a validated self-administered
family history questionnaire.9–12 Using a combination of
searching GP EHRs for patients with raised cholesterol,
with completion of a family history questionnaire, indivi-
duals with possible FH may be more actively and appro-
priately identiﬁed in primary care.
In line with Medical Research Council guidelines,13 this
feasibility study aimed to inform the development of an
intervention to identify FH more proactively in primary
care. We investigated if the approaches used, study proce-
dures and analysis were feasible, or might be enhanced,
prior to their use in a future randomised controlled trial
(RCT).13 We explored patients being targeted and
invited for further assessment of possible FH, opportunis-
tically when they consult, using computerised patient-
speciﬁc reminders when their serum cholesterol is above
diagnostic threshold (7.5 mmol/L) and was recorded in
electronic medical records.14 15 In addition, we explored
an approach of practices simply mailing all patients with a
cholesterol level ever recorded above diagnostic thresh-
old. The speciﬁc objectives were to gain experience of:
▸ patient recruitment, identiﬁcation, referral and diag-
nosis rates
▸ using opportunistic and universal postal recruitment
strategies
▸ whether relevant outcome measures for a proposed
trial may be extracted from automated searches of
GP EHRs.
METHODS
Study design
This was a feasibility study with process evaluation to
inform a RCT. The study duration was 17 months, ending
in August 2015, and was approved by NRES Committee
West Midlands—Solihull (Reference 12/WM/0322).
Participants
All 173 general practices in Nottinghamshire were
invited to participate in the study through the local
Primary Care Clinical Research Network, and we
received expressions of interest from 18 practices.
Further information was given to all 18 practices, and
the ﬁrst six eligible practices which responded, were
recruited to the study (4 inner city practices, 1 suburban
and 1 rural practice).
Eligible patients were aged 18 years or over at the start
of the study in the recruited general practices with a pre-
vious record, in the computer medical records, of choles-
terol at a level >7.5 mmol/L. Those who already had a
conﬁrmed diagnosis of familial hypercholesterolaemia
were excluded.
Intervention and procedure
The intervention began with a one-hour educational
session at each recruited practice. This involved an
update session on the identiﬁcation and investigation of
FH in line with current NICE guidelines,7 and linked to
Simon-Broome criteria.6 General practitioners were
familiarised with the proposed computer-based alert
message which appears when eligible patients’ medical
records are accessed. They were also given a laminated
sheet to use when eligible patients consulted their
general practitioners as an aide memoire for further
assessment. This outlined the Simon-Broome criteria,
and a prompt to investigate and exclude secondary
causes of hypercholesterolaemia such as diabetes, hypo-
thyroidism, chronic kidney disease and liver disease.
Following training, a baseline computer data extrac-
tion was completed which identiﬁed 831 eligible
patients, with cholesterol levels above 7.5 mmol/L from
the six practices. These patients’ EHRs were tagged with
an alert message to check for secondary causes of ele-
vated cholesterol, invite the patient to participate in the
study, repeat the lipid proﬁle and manage in line with
NICE guidelines/Simon-Broome criteria for FH.7 This
alert appeared when the individual’s computer records
were accessed. This opportunistic approach was contin-
ued for 6 months. Four months into the intervention, eli-
gible patients identiﬁed at baseline who had not already
been invited opportunistically, were all approached
through a postal invitation from their practice.
Eligible patients were given study packs by their
general practitioners opportunistically, or had them
mailed to them by their practice. These included study
information/consent and blood test forms to have a
follow-up fasting lipid proﬁle (comprising total choles-
terol, LDL cholesterol and triglyceride) unless lipid
proﬁle was done in the last 6 months, a Family History
and Symptom Questionnaire (FHSQ) seeking details on
family history of myocardial infarction and cholesterol,
together with photos to identify tendon xanthoma in
Box 1 Referral criteria for diagnosis: abridged Simon-
Broome diagnostic criteria
▸ In adults, total cholesterol >7.5 mmol/L and low density lipo-
protein >4.9 mmol/L.
▸ Plus for a diagnosis of possible familial hypercholesterolaemia
(FH), family history of myocardial infarction at age <60 years
in first-degree relative, age <50 years in second-degree rela-
tive, or a family history of raised cholesterol levels.
▸ Plus for a diagnosis of definite familial hypercholesterolaemia,
tendon xanthomata in patient or in first-degree or second-
degree relative.
▸ Patients with ‘definite’ or ‘possible’ familial hypercholesterol-
aemia should be referred to a specialist with expertise in famil-
ial hypercholesterolaemia, to confirm the diagnosis,
management and coordination of the testing of relatives.
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Achilles tendons and hands. The consent form and
FHSQ were returned to the research team ofﬁce, with
recruited patients’ participation in the study using a com-
puter recruitment code tagged onto the patient’s GP
EHRs. The research team then collated information on
fasting lipid results, current stain therapy, family history
and reported any possibility of FH diagnosis, in line with
Simon-Broome criteria (box 1) back to GPs to facilitate
contacting participants. Participants fulﬁlling Simon-
Broome criteria for possible FH were asked to arrange an
appointment with their general practitioner. The general
practitioners were advised to examine patients for signs
of FH, exclude secondary causes of raised cholesterol,
and refer those patients who met Simon-Broome criteria
to the local lipid specialist clinic. Those not fulﬁlling FH
diagnosis based on Simon-Broome criteria were reas-
sured, and a healthy living leaﬂet provided.
Outcome measurements
The primary measures assessed the feasibility of this
intervention (see box 2). Recruitment rate was
determined during the 6 month study period, while
referral, diagnosis and retention rate were assessed up
to 6 months after completing recruitment (12 months
after the start of the intervention). Diagnosis of con-
ﬁrmed FH in secondary care was based on clinical cri-
teria (ie, Simon-Broome criteria). Relevant outcome
measures for a proposed follow-up RCT were derived
from the primary care recommendations in the NICE
FH guidelines. This includes repeat testing for full lipid
proﬁle; excluding secondary causes of raised cholesterol
and collecting comprehensive family history. The feasi-
bility of extracting such data from GP EGRs was assessed
using both an automated process via medical codes and
a manual process in which a researcher reviewed
patients’ records, including free text entries and hos-
pital letters. This was performed 6 months after the
start of the intervention in each practice.
Statistical analysis
As a feasibility study, we assessed the feasibility of the
intervention, recruitment process and study instruments;
hence, a sample size for proposed outcome measure was
not appropriate. All primary outcome measures (recruit-
ment, referral, retention and diagnosis rates) were pre-
sented descriptively. For proposed trial outcome
measures (NICE guideline compliance), a descriptive
analysis presented numbers and percentages for all cat-
egorical variables; mean and SD for all continuous vari-
ables at 6-month follow-up. All analyses were conducted
in STATA 14 MP4.
RESULTS
Primary outcomes: feasibility of FAMCHOL study process
Recruitment rate
Figure 1 outlines the study recruitment process and pro-
cedure for the 831 eligible patients (2.36% of total)
identiﬁed at baseline from 35 438 patients, over 18 years,
registered with the six GPs.
Opportunistically, out of 207 study packs handed out,
41 (19.8% of study packs; 4.9% of all eligible patients)
completed consent forms and Family History/Symptom
Questionnaire. At 4 months, 802 study packs were
mailed out to the outstanding eligible participants, and
an additional 86 (10.7% all mail-outs; 10.3% of all eli-
gible patients) were recruited using this systematic
approach. By the end of the 6-month recruitment
process, 127 patients consented and were recruited to
the study which gave an overall response and engage-
ment rate of 15.3%, (ranging from 7.9% to 15.8% at the
four inner city practices, 13.9% at the suburban practice
and 26.7% at the rural practice).
Identification and referral rate
Among the 127 consenting patients, 125 could be
assessed for FH against Simon-Broome criteria. One
patient declined follow-up blood lipids, and another
Box 2 FAMCHOL feasibility study outcome measures
assessed
Primary measures
▸ Recruitment rate;
▸ Referral rate;
▸ Diagnosis rate:
– Possible familial hypercholesterolaemia (FH) identified
primary care,
– Possible FH confirmed by secondary care,
– Definite FH confirmed by secondary care;
▸ Retention rate;
Extracting relevant outcome measures for proposed trial
▸ Cholesterol level:
– Latest total cholesterol levels (mmol/L),
– Latest low density lipoprotein (LDL) cholesterol levels
(mmol/L),
– Proportion of patients who have a total cholesterol
≥7.5 mmol/L or LDL-C ≥4.9 mmol/L;
▸ Repeat cholesterol (lipid profile) test;
▸ Patients diagnosed with secondary cause (diabetes, hypothy-
roidism, chronic kidney disease, liver disease);
▸ Family history of coronary heart disease assessed;
▸ Quality of coronary heart disease family history assessed (age,
condition, degree of relation);
▸ Thyroid stimulating hormone assessment (proxy for hypothy-
roidism investigations);
▸ HbA1c assessment (proxy for diabetes investigation);
▸ Serum creatinine assessment (proxy for chronic kidney
disease investigations);
▸ Bilirubin, alkaline phosphatase (ALP) or glutamyl transpepti-
dase (gamma GT) assessment (proxy for liver disease);
▸ Arcus senilis or xanthalasma diagnosed;
▸ Proportion of patients prescribed statins;
▸ Proportion of patients prescribed high potency statins treat-
ment (simvastatin ≥80 mg/day; atorvastatin ≥20 mg/day;
rosuvastatin ≥10 mg/day)
▸ Dietary or weight management advice;
▸ Smoking cessation advice.
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patient had previously been diagnosed with familial
hypercholesterolaemia on more detailed review of previ-
ous medical records. Thirty-two (25.6% of 125 eligible
for assessment) patients had a possible diagnosis of FH
and were invited to see their general practitioners.
Fourteen patients (43.8% of 32 with possible FH) were
actually seen by their general practitioner, while four
patients declined the appointment and 14 patients did
not respond to the invitation. Subsequently, nine
patients (64.2% of 14 seen by GPs) were referred to
lipid specialist. Further, seven patients (77.8% of the
nine referred by GPs) were actually seen by specialists, as
one patient declined the referral appointment and the
other patient’s referral could not be found in secondary
care by the 12-month study period end.
Diagnosis rate
Of the seven patients with probable FH referred and
seen by a specialist, two patients (28.6%) were con-
ﬁrmed with deﬁnite FH (by specialist examination) and
ﬁve patients (71.4%) were conﬁrmed with possible FH
(mutation-negative for monogenic FH).
Proposed trial outcomes: feasibility of data extraction
From 127 participants recruited, data on clinical records
from 118 (95%) patients could be extracted from GP
EHRs. Data from seven patients were excluded from the
analysis due to transferring from practice. Table 1 details
patient clinical characteristics based on the proposed
outcome measures for 118 patients at 6 months from
the start of the intervention through automated
Figure 1 FAMCHOL study
procedure and process. FH,
familial hypercholesterolaemia;
GP, general practice.
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extraction from GP EHRs. Although all patients had a
cholesterol assessment completed, 3% (n=4) of the
sample did not have the LDL cholesterol measurement
documented into their EHRs.
Among the 118 recruited patients, there were more
men than women (61% men, 39% women), with an
average age being 58 years (SD 9.0) for men and
56 years (SD 7.5) for women. The latest mean total chol-
esterol was 5.8 mmol/L (SD 1.5) and 6.4 mmol/L (SD
1.4) for men and women, respectively. The mean LDL
cholesterol was 3.6 mmol/L (SD 1.3) and 3.8 mmol/L
(SD 1.5) for men and women, respectively. Additionally,
12 men (26%) and 23 women (32%) were found to
have an elevated total or LDL-cholesterol. All outcome
measures extracted purely from automated process are
presented in table 1.
Considering other measures, manual extraction only
showed a small absolute increase in number of patients
diagnosed with a secondary causes of hypercholesterol-
aemia (men: +2%; women +3%), statin prescribing
(men: +1%; women +4%), and in smoking cessation
advice given (men: +2%; women: +8%). The low level of
family history recording, particularly when identifying a
‘complete family history’, was only slightly improved by
an absolute increase of 5% for both men and women
(+2 men; +4 women) when manually extracting free text
in the GP EHRs. However, in manual extraction, GPs
arranged and documented more investigations for sec-
ondary causes (thyroid stimulating hormone: +30% for
men; +36% for women; HbA1c: +18% for men, +33%
for women; serum creatinine: +55% for men, +56% for
women; liver function test: +52% for men, +58% for
women), and dietary or weight management advice
given (men: +12%; women: +20%). In automated com-
puter data extraction, clinical features of FH (arcus
senilis or xanthalasma) were not recorded, while in
manual search, 7% (1 man; 7 women) of all participants
had arcus senilis or tendon xanthalasma documented in
free text.
DISCUSSION
This study showed that it is feasible to engage and
recruit patients with raised cholesterol for more system-
atic identiﬁcation of familial hypercholesterolaemia in
primary care, both through opportunistic GP contact
and by postal invitation. Although postal invitation
resulted in more eligible patients being recruited than
opportunistic invitation, the latter had double the
response rate. This suggests both strategies should be
Table 1 Proposed outcome measures extracted from primary care computer records using an automated extraction at the
end of the study period
Patient outcome measures Male (n=46) Female (n=72)
Age (years) 58 (9.0) 56 (7.5)
Total cholesterol (mmol/L) 5.8 (1.5) 6.4 (1.4)
LDL cholesterol (mmol/L) 3.6 (1.3) 3.8 (1.5)
Number with latest TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L (%) 12 (26) 23 (32)
Number with repeat cholesterol test within 6 months after study start date (%) 41 (89) 60 (83)
Number of diagnosed with secondary cause* within 6 months after study start date (%) 5 (11) 5 (7)
Number with any family history of coronary heart disease assessed within 6 months after
study start date (%)
14 (30) 31 (43)
Number with any complete family history† of coronary heart disease assessed within
6 months after study start date (%)
1 (2) 6 (8)
Number with TSH assessed within 6 months after study start date‡ (%) 14 (30) 17 (23)
Number with HbA1c assessed within 6 months after study start date§ (%) 6 (13) 17 (24)
Number with serum creatinine assessed within 6 months after study start date¶ (%) 19 (41) 29 (40)
Number with bilirubin, ALP or gamma GT assessed within 6 months after study start
date** (%)
19 (41) 22 (31)
Number with arcus senilis or xanthalasma diagnosed within 6 months after study start
date (%)
0 (0) 0 (0)
Number of prescribed any statins within 6 months after study start date (%) 14 (30) 13 (18)
Number of prescribed high-potency statins†† within 6 months after study start date (%) 4 (9) 2 (3)
Number of given dietary or weight management advice within 6 months after study start
date (%)
27 (59) 33 (46)
Number of given smoking cessation advice within 6 months after study start date (%) 19 (41) 15 (21)
Variables are means and SDs unless otherwise specified.
*Diabetes, hypothyroidism, chronic kidney disease, liver disease.
†Complete family history is defined when age, condition and degree of relation to patient is documented.
‡Proxy for secondary investigations for hypothyroidism.
§Proxy for secondary investigations for diabetes.
¶Proxy for secondary investigations for chronic kidney disease.
**Proxy for secondary investigations for liver disease.
††Simvastatin ≥80 mg/day, atorvastatin ≥20 mg/day, rosuvastatin ≥10 mg/day.
ALP, alkaline phosphatase; GT, glutamyl transpeptidase; LDL, low density lipoprotein; TC, total cholesterol; TSH, thyroid stimulating hormone.
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adopted for patient recruitment in any future study.
While only a feasibility study, new cases of deﬁnite FH
were identiﬁed in the current work who are now on
appropriate treatment and management pathways to
reduce their previously elevated cardiovascular risk.
By using automated GP computer searches, we were
able to capture relevant outcome measures for a pro-
posed trial on lipid testing, statin prescribing and pos-
sible secondary causes of hypercholesterolaemia, without
burdening patients and clinicians with data collection
forms. This could potentially improve collating such
outcome measures in this and other studies.
Strengths and limitations
The majority of practices recruited to this study (four
out of six) were from socially disadvantaged inner city
populations where prior identiﬁcation rates of FH were
likely to be lower. Although one afﬂuent rural practice
accounted for nearly half the recruited participants, the
approaches used successfully recruited patients from
practices with underserved populations. In addition, suc-
cessful extraction of outcome data from GP health
records was achieved from 95% (118) of recruited
patients using automated searches.
Owing to the pragmatic nature of this study, some
patients may have received the recruitment packs twice
(opportunistic and systematic). However, for ethical
reasons, we could not identify patients given recruitment
packs opportunistically, and did not consent to partici-
pate in the study. In terms of identifying eligible
patients, we recognised that eligibility criteria did not
consider the effects of statin treatment. There were indi-
viduals who had cholesterol levels below the 7.5 mmol/L
threshold who were already on statins at the time of
recording highest cholesterol level in the electronic
medical records. If these treatment effects were consid-
ered,16 there may be more eligible patients than we pre-
viously thought. Additionally, recruitment of eligible
patients to the study may have been inﬂuenced by
healthcare policy and a gender bias in recruitment. The
National Health Service vascular check programme
screens17 offers CVD risk assessment for age range of
40–75 years and previous evidence18 have shown that
women are more likely to join a general cardiovascular
disease screening programme than men. Finally, the
follow-up period of 6–12 months may have been too
short for the outcome of specialist referral to be fed
back into a patient’s GP records.
Clinical implications
Patients with deﬁnite FH have been identiﬁed from
this study and are now beneﬁting from treatment to
reduce their greatly elevated risk of premature
CHD. Further, this allows for cascade screening of add-
itional family members from deﬁnite cases of FH in
secondary care, an approach that is known to be cost-
effective.19–22
Future research
This intervention, to more systematically identify patients
with familial hypercholesterolaemia, is feasible to imple-
ment in GP, and facilitates successful recruitment of
patients with raised cholesterol for appropriate assess-
ment and referral to secondary care. Opportunistic
recruitment may be improved in future studies by
researchers more actively engaging with GP administra-
tive and clinical staff, and by seeking to enhance effect-
ive implementation strategies,23 such as ensuring that
study packs are available in all consultation rooms and
repeated in-practice audit and feedback on the beneﬁts
of FH identiﬁcation. To improve future implementation,
we are currently assessing the post-study changes in prac-
titioner behaviour on relevant clinical outcomes, such as
family history and diagnosis of secondary causes, as well
as the qualitative experience of those patients and
healthcare professionals who participated in this study,
including patients who declined follow-up.24
Using current (Simon-Broome) criteria, a large pro-
portion of patients with possible FH are identiﬁed but
not conﬁrmed to have FH on specialist assessment.
More resource-effective approaches to identify FH need
to be developed.25–28 For instance, our recently devel-
oped approach (Familial Hypercholesterolaemia Case
Acertainment Tool)27 from routinely available data, held
in primary care EHRs, takes into account patients
already on statins, secondary causes of raised cholesterol,
triglycerides and premature CHD when identifying
patients who may have FH.
The parameters derived in this study on eligibility,
recruitment and diagnosis will directly inform a future
cluster RCT in primary care. In any future trial, diagno-
sis of FH should be based on both clinical assessment
and genetic testing. For a future trial in a large number
of GPs, manual computer data extraction would likely
not be feasible. Extraction of pseudoanonymised data
from EHRs demonstrated in this and other related
studies29 can rapidly capture key trial outcome measures
without burdening patients, for example, with forms
seeking detailed information which may reduce
response rates.30 Nevertheless, coded (automated) data
extraction needs to be improved, for example, by incorp-
orating computer templates to collate process data and
outcomes of referral. Other outcomes measures with low
levels of recording, or not routinely assessed in primary
care, such as detailed family histories and physical signs
of FH (xanthalasma and arcus senilus), need to be sup-
plemented by additional clinician training and facili-
tated data capture using validated questionnaires. Any
future robust trial will need to adopt a cluster-
randomised design with a follow-up duration of at least
12 months. The trial sample size should also take
account of patients already on statins with pre-treatment
cholesterol above the threshold.
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